Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2007-10-11 13:51 |
Pharming receives Orphan Drug designation for recombinant fibrinogen from FDA
|
English | 82.1 KB | ||
| 2007-10-11 13:51 |
Pharming receives Orphan Drug designation for recombinant fibrinogen from FDA
|
English | 88.3 KB | ||
| 2007-09-20 08:30 |
Pharming To Present At UBS Global Life Sciences Conference
|
English | 59.7 KB | ||
| 2007-09-20 08:30 |
Pharming To Present At UBS Global Life Sciences Conference
|
English | 61.8 KB | ||
| 2007-09-19 08:46 |
Pharming participates in BioMedical Materials program
|
English | 68.5 KB | ||
| 2007-09-19 08:46 |
Pharming participates in BioMedical Materials program
|
English | 65.8 KB | ||
| 2007-08-30 08:46 |
PHARMING PRESENTS POSITIVE RESULTS FROM EUROPEAN PHASE III TRIAL OF RHUCIN®
|
English | 83.4 KB | ||
| 2007-08-30 08:46 |
PHARMING PRESENTS POSITIVE RESULTS FROM EUROPEAN PHASE III TRIAL OF RHUCIN®
|
English | 83.2 KB | ||
| 2007-08-20 14:14 |
Pharming Reports Positive Results In European Placebo-controlled Trial Of Rhuci…
|
English | 80.7 KB | ||
| 2007-08-20 14:14 |
Pharming Reports Positive Results In European Placebo-controlled Trial Of Rhuci…
|
English | 81.5 KB | ||
| 2007-07-20 10:18 |
Pharming announces first half 2007 results
|
English | 109.6 KB | ||
| 2007-07-20 10:18 |
Pharming announces first half 2007 results
|
English | 112.1 KB | ||
| 2007-07-13 08:34 |
Pharming facilities obtain GMP status
|
English | 70.5 KB | ||
| 2007-07-13 08:34 |
Pharming facilities obtain GMP status
|
English | 60.2 KB | ||
| 2007-06-28 13:59 |
Pharming Provides Portfolio And Technology Update At Company Meeting
|
English | 64.6 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
